SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Kelly Services, Inc. engages in the provision of talent solutions. It operates through the following segments: Professional and Industrial, Science, Engineering, and Technology, Education, Outsourcing and Consulting, and International. The Professional and Industrial segment includes the provision of administrative, accounting and finance, light industrial, contact center staffing, and other workforce solutions. The Science, Engineering, and Technology segment focuses on staffing, outcome-based, permanent placement services, clinical research, and telecommunications. The Education segment involves offering education and therapy services talent through staffing, permanent placement, and executive search services to Pre-K-12 school districts and organizations. The Outsourcing and Consulting segment consists of global talent supply chain and workforce solutions, including Managed Service Provider (MSP), Recruitment Process Outsourcing (RPO), Payroll Process Outsourcing (PPO), and executive coaching programs. The company was founded by William Russell Kelly on October 7, 1946 and is headquartered in Troy, MI.

Kelly Services, Inc. - Ordinary Shares - Class B

Kelly Services is experiencing intense volatility driven by its extremely low float and active accumulation by institutional players and insiders, which has fueled widespread community speculation about a potential short squeeze. Traders are closely monitoring upcoming earnings and corporate conference calls as potential catalysts for further upward movement.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently the focal point of intense market volatility, driven by a combination of disappointing quarterly delivery figures, broader geopolitical instability in the Middle East, and active investor speculation regarding the company's valuation as a proxy for Elon Musk's wider ventures, including the upcoming SpaceX IPO. Community sentiment is deeply polarized, with traders aggressively debating whether to treat the stock as a distressed automotive manufacturer or a long-term play on AI and robotics, while many are actively using options to hedge or capitalize on the heightened price fluctuations.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Kennedy Space Center, FL.

Starfighters Space Inc

Starfighters Space (FJET) is experiencing heightened trading activity fueled by speculative interest in the broader space sector, specifically anticipation surrounding a potential SpaceX IPO and the company's recent operational updates at the Midland Air & Space Port. The stock remains a major talking point among retail investors, who are actively debating the company's long-term viability versus the potential for a volatile short squeeze given its small float and high short interest.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The SPY is currently trading in a highly volatile, news-driven environment where investors are attempting to reconcile a significant spike in oil prices with a resilient equity market. Market participants remain deeply divided and cautious, with heavy debate focusing on whether the current price action is a genuine reversal or a manipulative bull trap designed to liquidate option premiums ahead of the long holiday weekend.

Invesco QQQ Trust Series 1 - Units of beneficial interest

The Invesco QQQ Trust is experiencing intense volatility driven by conflicting signals between rising oil prices and algorithmic buying, leading to significant friction between bearish sentiment over geopolitical instability and bullish institutional accumulation. Community discussion is dominated by intense frustration over market manipulation, with retail traders debating whether the rapid price swings represent a sustainable rally or a deceptive trap ahead of the upcoming holiday weekend.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors position for upcoming earnings, buoyed by the integration of QNX technology into major automotive partnerships and strategic shifts toward software-defined vehicle infrastructure. Community sentiment remains polarized, with bullish long-term investors highlighting the growing royalty backlog and safety-critical moat as catalysts for a potential reversal, while skeptics remain focused on past revenue performance and management guidance.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is seeing heavy volatility as traders debate the sustainability of its parabolic rally following its S&P 500 inclusion and massive AI-driven infrastructure demand. The community is sharply divided between bulls citing mission-critical optical networking bottlenecks and bears warning of a potential liquidity trap or bubble valuation.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is rallying as the space sector gains momentum ahead of the Artemis II mission launch, with investors closely watching for impact on the broader orbital infrastructure market. The community remains highly active, debating the potential for a short squeeze while contrasting current mission optimism against lingering concerns over share offerings.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

United States Oil Fund is surging as traders react to heightened geopolitical tensions in the Middle East following official comments that military operations in Iran will continue, fueling fears of sustained energy supply disruptions. The community is heavily focused on the potential for a prolonged conflict and its inflationary impact, with active debates centered on whether oil prices are entering a long-term structural uptrend or if the current market action is a temporary headline-driven squeeze.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is trending as investors monitor the early commercial launch of its FDA-approved therapy YARTEMLEA and await updates on potential milestone payments from its partnership with Novo Nordisk. Community discussion is heavily focused on the stock's undervaluation relative to its pipeline potential, the impact of significant short interest, and optimism surrounding upcoming European regulatory decisions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Guggenheim Has Lowered Expectations for Unicycive Therapeutics (NASDAQ:UNCY) Stock Price

Guggenheim decreased their price target on Unicycive Therapeutics from $46.00 to $40.00 and set a "buy" rating on the stock in a research note on Thursday...

Noble Financial Has Positive Forecast for UNCY Q1 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Equities research analysts at Noble Financial increased their Q1 2026 earnings per share (EPS) estimates for shares of Unicycive...

<ul class="summary-bullets"><li>The FDA is expected to decide on the application by June 29, as per the company.&nbsp;</li><li>The FDA in June refused to approve the company’s application citing manufacturing issues at a third-party manufacturing vendor.&nbsp;</li><li>The company is now looking to launch OLC in the third quarter.</li></ul>Shares of Unicycive Therapeutics Inc (UNCY) jumped 9% on Wednesday as retail investors contemplated the possibility of approval for the company’s Oxylanthanum carbonate.UNCY has resubmitted its application seeking the U.S. Food and Drug Administration’s approval for Oxylanthanum carbonate for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis following a previous rejection. The FDA is expected to decide on the application by June 29, as per the company.The FDA in June refused to approve the company’s application citing manufacturing issues at a third-party manufacturing vendor.The company is now looking to launch OLC in the third quarter and is continuing to strengthen its commercial infrastructure and advance market readiness initiatives in the meantime.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around UNCY jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels. Over the past week, message volume rose 150%, according to Stocktwits data.A Stocktwits user predicted revenue of as much as $600 million for OLC in 2029.<stembedurl>https://www.stocktwits.com/Thrasher5699/message/649190093</stembedurl>Yet another sees 80% chances for the drug’s approval this time.<stembedurl>https://www.stocktwits.com/Cvfiore2001/message/649096819</stembedurl><h2 class="st-heading-2">Unicycive Therapeutics Inc Management Commentary</h2>“This year is shaping up to be pivotal for Unicycive, underscored by the U.S. Food and Drug Administration’s acceptance of our New Drug Application resubmission for OLC and the potential for approval and launch later this year,” said CEO Shalabh Gupta earlier this week. “With hyperphosphatemia still uncontrolled in nearly 75% of U.S. patients with chronic kidney disease undergoing dialysis, OLC, if approved, has the potential to offer a meaningful new treatment option characterized by a differentiated clinical profile and reduced pill burden compared to currently available phosphate binders.”Hyperphosphatemia is a condition characterized by excessively high levels of phosphate in the blood.<a href="https://stocktwits.com/symbol/UNCY">UNCY stock </a>has gained nearly 32% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/lly-stock-rallies-on-much-awaited-fda-approval-for-weight-loss-pill/cZ7Hp5ORIF5">LLY Stock Rallies On Much Awaited FDA Approval For Weight Loss Pill</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.<div class="st-video-embed" data-video-url="https://videos.stocktwits-cdn.com/hls/2026/03/26/69ee8298-8c28-42e1-b686-43e84dc29610/fq6gh7vs9vzzy7rkkx2fll5vlsu3_download.mp4" data-thumbnail-url="" data-caption="" data-summary="" data-width="" data-height="" data-orientation="horizontal" data-duration="">&nbsp;</div>

Rising stock market chart on a trading board background.

UNCY Retail Buzz Explodes 150% This Week as Traders Bet Big on Experimental Drug Approval

UNCY has resubmitted its application seeking the U.S. Food and Drug Administration’s approval for Oxylanthanum carbonate for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. 

Equity

UNCY has resubmitted its application seeking the U.S. Food and Drug Administration’s approval for Oxylanthanum carbonate for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. 


Noble Financial Brokers Boost Earnings Estimates for UNCY

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Stock analysts at Noble Financial increased their Q3 2026 earnings per share estimates for Unicycive Therapeutics in a research report...

Unicycive Therapeutics (NASDAQ:UNCY) Releases Quarterly Earnings Results, Misses Estimates By $0.36 EPS

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) released its earnings results on Monday. The company reported ($0.82) earnings per share for the quarter, missing analysts' consensus estimates...

Unicycive Therapeutics (UNCY) to Release Quarterly Earnings on Monday

Unicycive Therapeutics (NASDAQ:UNCY) will be releasing earnings before the market opens on Monday, March 30. (View Earnings Report at...

Unicycive Therapeutics (NASDAQ:UNCY) Shares Down 0.4% - Here's Why

Unicycive Therapeutics (NASDAQ:UNCY) Trading Down 0.4% - Should You Sell...

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Recommendation of "Moderate Buy" by Analysts

Shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the five brokerages that are currently covering the firm...

Unicycive Therapeutics (NASDAQ:UNCY) Stock Price Up 2.4% - Should You Buy?

Unicycive Therapeutics (NASDAQ:UNCY) Stock Price Up 2.4% - Still a Buy...

Analysts Set Expectations for UNCY FY2030 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Analysts at HC Wainwright issued their FY2030 earnings per share estimates for Unicycive Therapeutics in a research report issued on Monday...

Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

UNCY
Unicycive Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest UNCY News

UNCYUnicycive Therapeutics Inc